Andere talen Foghorn Therapeutics Inc.

Aandelen

FHTX

US3441741077

Geschatte realtime Cboe BZX Andere beurzen 21:08:55 19-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
5,17 ^USD	-6,51%		-29,92%	-19,38%

09/04	Transcript : Foghorn Therapeutics Inc. - Special Call
07/03	Foghorn Therapeutics Inc. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Foghorn Therapeutics Names Kristian Humer CFO	16/04
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer	16/04
Foghorn Therapeutics Inc. Appoints Kristian Humer as Chief Financial Officer	16/04
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs	09/04
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference	05/04
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting	26/03
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07/03
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook	07/03
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909	05/03
Foghorn Therapeutics Inc. to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, Including the Selective Inhibitor of BRM, FHD-909	05/03
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference	28/02
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference	28/02
Eli Lilly : un antitumoral de Foghorn a été sélectionné	08/02
Foghorn Shares Rally as Eli Lilly Plans Clinical Program With Oncology Product	08/02
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	08/02
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor	08/02
Foghorn Therapeutics Inc. Appoints Stephen J. Dipalma Interim Chief Financial Officer, Effective January 16, 2024	17/01
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024	08/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Foghorn Therapeutics Inc.

Aandelen

FHTX

US3441741077

Andere talen

Filters